NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:

Similar documents
Hepatitis C Management and Treatment

HCV Epidemiology, Screening, Natural History, and Extra-Hepatic Manifestations

Hepatitis C. David Byers, MD, FACP Senior Medical Director for Infectious Diseases and Wound Healing Services Southern Ohio Medical Center

Commonly Asked Questions About Chronic Hepatitis C

Hepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011

Hepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003

The ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses

Hepatitis C. Core slides

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

HCV in the Latino Community -Epidemiology, Natural History, Risk Factors, Screening and Diagnosis

What is Hepatitis C Virus (HCV)?

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

Hepatitis C. No disclosures. 1. The USPSTF recommends Hepatitis C screening in which patient populations?

-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual

Hepatitis C in Australia:

Hepatitis C Virus (HCV)

Epidemiology and Screening for Hepatitis C Infection

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016

Liver Cancer Causes, Risk Factors, and Prevention

Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm

i Screening and Natural History

EAST LONDON INTEGRATED CARE

Strategies to Address HCV

Digestive & Liver Disease Wellness

Bible Class: Hepatitis B Virus Infection

Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016

ADDRESSING VIRAL HEPATITIS IN PEOPLE WITH SUBSTANCE USE DISORDERS: A THREE (3) PART SERIES

Agenda. Hepatitis C: Evaluation & Treatment. Background. Natural History of Hepatitis C. Epidemiology 9/23/2014

Outline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018

Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious Disease & Laboratory Sciences

Update on HIV-HCV Epidemiology and Natural History

Epidemiology of Hepatitis C Iran

Viral Hepatitis B and C in North African Countries

Hepatitis C wi w t i h Ju J dy y W y W a y t a t t

IN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST

Geo-epidemiology of Hepatitis C in Northeast Indiana

CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE

Chronic Hepatitis B Infection

HBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

Hepatitis C: Let s Talk About It. Causes of Hepatitis

Viral Hepatitis. WHO Regional Office for Europe July 2013

EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE

Elaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus / Fax

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

Uses and Misuses of Viral Hepatitis Testing. Origins of Liver Science

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

ACTIVITY DISCLAIMER. Kurt Cook, MD, MSc DISCLOSURE. Audience Engagement System. Learning Objectives

"Hepatitis" means inflammation of the liver and also refers to a group of viral infections that

Healthy Liver Cirrhosis

Hepatitis C in Disclosures

2016: The State of HIV & Hepatitis C in the District

HEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014

Hepatitis B and C Basics

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Before we begin. If you received a white card when you came in please read it and answer this question: What is the risk of Hep C with this activity?

Transmission/Prevention

North Africa) The prevalence of CHB varies widely across EMEA (Europe, Middle East & 8% High 2 8% Intermediate <2% Low

Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College

Chronic Hepatitis C. Risk Factors

C 肝職業暴露後之處置 衛福部疾病管制署 中區傳染病防治醫療網 王任賢指揮官

STOP Hepatocellular Carcinoma

Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre

Transmission of HCV in the United States (CDC estimate)

An Update HBV Treatment

THIS ACTIVITY HAS EXPIRED. CME CREDIT IS NO LONGER AVAILABLE

You, Your Liver and Hepatitis C

Jackie Williams BBV/Sexual Health Trainer

Hepatitis C Virus (HCV): Current Screening Guidelines and Treatment Approaches

Update on Hepatitis B and Hepatitis C

Hepatitis C Best Practice Guidelines For Local Health Departments

Hepatitis Case Investigation

Viral Hepatitis. Background

Bible Class: HCV Infection

HEPATITIS C LESSONS PART 1

Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques

Media centre. WHO Hepatitis B. Key facts. 1 of :12 AM.

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

How does HBV affect the liver?

HIV and PEP. LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED

HCSP TRAINING MANUAL

The Long Term Care Risk

Module 1 Introduction of hepatitis

Detection of Hepatitis B and C in Primary Care

Hepatology For The Nonhepatologist

Hepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology

EVALUATION OF ABNORMAL LIVER TESTS

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals

CONTR. The Centers for Disease Control and Prevention (CDC) has recently published

X-Plain Hepatitis B Reference Summary

Blood Borne Pathogens. Becky Walch, R.N. Micheel Valdez, L.V.N.

You have been diagnosed with chronic hepatitis C. I I

Swiss Summary of the Risk Management Plan (RMP) for. Vosevi, film-coated tablets

Training Objectives. Provide a basic understanding of:

Public Health Response to HCV in Oregon: Need for Screening and Treatment. Ann Thomas, MD, MPH Acute and Communicable Disease Prevention

Contents: 7. Transmission 8. Prevention 9. Testing 10. Living with Hepatitis C 11. Treatments 12. Co-infection 13. Support

Transcription:

ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis C BLOOD BORNE VIRUS Unlike HBV - rarely sexually spread Monogamous couples at low risk: 1-3% risk Increasing number of sexual partners HIV co-infection associated with higher rates of sexual spread 20% risk 0 1 SCREENING FOR HEPATITIS C: WHO SHOULD BE CHECKED? PATIENTS SHOULD BE TESTED IF THEY MEET ANY OF THE FOLLOWING HAVE KNOWN RISK FACTORS FOR VIRAL HEPATITIS INDICATE POSSIBLE RISK FACTORS FOR HEPATITIS HAVE ELEVATED LIVER ENZYMES PATIENTS WHO WANT TO BE SCREENED ALL HIV POSITIVE PATIENTS BORN BETWEEN 1945-1965* 1965* NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, 1997. NIH Web site. Available at: http://consensus.nih.gov/1997/1997hepatitisc105html.htm. Accessed January 24, 2006. *CDC MMWR VOL 61/ NO.4 AUGUST 17, 2012 Risk Factors for Contracting Hepatitis C History of ANY IV drug use (even only once ) Blood transfusion PRIOR June 1992 Given blood products before 1987 (ie. clotting factors) History of intranasal drug use ( snorting ) Tattoos (esp if done non-profess, or while incarerated) Body piercing (non-profess) Diagnosed with an STD (HCV NOT classified as STD, BUT can be) Any known blood exposure (work related or otherwise) 2 3 1

HCV: Perinatal Transmission Related to viral load Increased with HIV Increased risk with acute infection in 3rd trimester Overall risk approx. 5% Breast feeding is not a risk factor Nosocomial Exposure Contaminated equipment Rare in the U.S. except in hemodialysis (prevalence 10->60%) HCV(+) increase with increasing years on hemodialysis Health-care, emergency medical and public safety workers (needle stick) 1-2% Needle Stick in Health Care Workers HIV 0.4% HCV 3% HBV 30% 4 5 Natural History of Hepatitis C 10-20 years Acute Hepatitis C Chronic Hepatitis 75%-85 % Cirrhosis 20 % 6 Hoofnagle JH Hepatology. 1997;26 (suppl 1): 15S-20S Di Bisceglie, Hepatology, 2000 7 2

DON T JUST LOOK AT THE ENZYMES! SCREENING AND DIAGNOSIS OF HEPATITIS C SINGLE NORMAL ALT LEVEL DOES NOT RULE OUT CHRONIC VIRAL HEPATITIS ALT LEVELS MAY BE INTERMITTENTLY NORMAL IN A SIGNIFICANT NUMBER OF PATIENTS WHO HAVE CHRONIC HEPATITIS C A SINGLE NORMAL ALT 8 ALT=alanine aminotransferase. 9 ACUTE HCV INFECTION: PROGRESSION TO RECOVERY DOES HAPPEN - BUT RARELY ACUTE HCV INFECTION: PROGRESSION TO CHRONIC INFECTION MOST LIKELY PATTERN 85% ANTI-HCV ANTI-HCV SYMPTOMS + SYMPTOMS + ITER HCV RNA ITER HCV RNA T T ALT ALT ALT NORMAL NORMAL 0 1 2 3 4 5 6 1 2 3 4 0 1 2 3 4 5 6 1 2 3 4 MONTHS TIME AFTER EXPOSURE YEARS MONTHS TIME AFTER EXPOSURE YEARS RNA=ribonucleic acid. Morbidity and Mortality Weekly. Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. Centers for Disease Control. October 16, 1998/47(RR19);1-39. Morbidity and Mortality Weekly. Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. Centers for Disease Control. October 16, 1998/47(RR19);1-39. 10 11 3

HEPATITIS C VIRUS RNA TESTS DETERMINE PRESENCE OF ACTUAL VIRUS, NOT ANTI-HCV ANTIBODIES HELPFUL IN DIFFICULT CASES ANTIBODY TESTS INCONCLUSIVE COMPROMISED IMMUNE SYSTEM EXPENSIVE AND REQUIRES SPECIAL HANDLING SENSITIVITY MAY VARY BETWEEN LABS; DEPENDS ON TYPE OF ASSAY CHECK LOWER LIMIT OF DETECTION 12 HCV Genotypes and Subtypes Developed countries South Africa Middle East North Africa IVDU 4 5 3 2 Simmonds P, Journal of Hepatology, 1999 Americas + Western Europe Asia 6 1 13 LIVER BIOPSY HISTOLOGIC STAGING MAY BE GUIDED BY CT OR ULTRASOUND PROVIDES INFORMATION REGARDING DEGREE OF INFLAMMATION DISEASE SEVERITY TISSUE DAMAGE PRESENCE/ABSENCE OF CIRRHOSIS HELPS DETERMINE DEGREE OF DISEASE PROGRESSION CAUSE OF LIVER DISEASE NEED FOR TREATMENT STAGE 0 NO FIBROSIS STAGE 3 NUMEROUS SEPTA STAGE 1 STAGE 2 PORTAL FIBROSIS FEW SEPTA STAGE 4 CIRRHOSIS CT=computed tomography. 14 15 4

FACTORS WHICH MAY INFLUENCE THE OUTCOME OF HEPATITIS C VIRUS -LOAD -GENOTYPE -QUASISPECIES HOST -SEX -AGE -RACE -GENETICS -IMMUNE ENVIRONMENT -ALCOHOL - HBV -HIV -DRUGS -STEATOSIS -IRON -NASH 16 HBV=hepatitis B virus; HIV=human immunodeficiency virus; NASH=nonalcoholic steatohepatitis. Alberti A et al. J Hepatol. 1999;31(suppl 1):17-24. 17 GOALS OF HCV THERAPY OF HCV T SUSTAINED VIROLOGIC PRIMARY: CLEARANCE OF VIRUS PRODUCE A MAINTAIN A SUSTAIN A AFTER COMPLETION OF TX SECONDARY: INHIBITION OF DISEASE PROGRESSION REDUCTION OF INCIDENCE OF HCC REDUCTION IN NEED FOR LIVER TRANSPLANT VIRAL LO OAD SVR RNA=ribonucleic acid. 18 Adapted from Pawlotsky JM et al. Hepatology. 2000;32:654-659. 19 5

PATTERNS OF HCV RESISTANCE OF HCV R PRODUCE A MAINTAIN A NON D VIRAL LOAD BREAKTHROUGH RELAPSE Adapted from Pawlotsky JM et al. Hepatology. 2000;32:654-659. 20 6